VitriVax

Executive Summary

VitriVax is a Boulder-based biotechnology company developing thermostable, single-dose vaccine formulations using its proprietary ALTA® platform. Founded in 2019, the company aims to eliminate barriers to global vaccination by enabling vaccines that do not require cold-chain storage and can be administered in a single shot. The ALTA platform encapsulates antigens in a stable, controlled-release matrix, potentially simplifying logistics and improving coverage in low-resource settings. While still in early stages, VitriVax's technology has generated interest for its potential to transform vaccine delivery for infectious diseases, both pandemic and endemic. The company is privately held with undisclosed funding, but its innovative approach could attract strategic partnerships or further investment to advance preclinical and clinical development. Key risks include technical challenges in formulation stability and the need for clinical validation, as well as competition from other thermostable vaccine technologies.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Financing Round70% success
• H2 2026Partnership with Major Vaccine Developer50% success
• Q4 2026Preclinical Data Readout for Lead Candidate60% success